-
公开(公告)号:US20220380469A1
公开(公告)日:2022-12-01
申请号:US17762215
申请日:2020-09-23
发明人: Gursel Aktan , Roger Delemere Dansey , Vassiliki Karantza , Zifang Guo , Jaime A. Mejia , Shu-Chih Su , Jing Zhao , Xuan Zhou
摘要: The present invention relates to methods for treating metastatic triple negative breast cancer in a human patient which has been identified as having a PD-L1 enriched tumor comprising administering, as monotherapy, an anti-PD-1 antibody or antigen binding fragment thereof (e.g., pembrolizumab) in specific amounts to the patient about every three or six weeks, wherein the PD-L1 enriched tumor is a tumor identified as having a CPS score of ≥10.